Monaco Asset Management SAM Has $1.08 Million Holdings in Novavax, Inc. (NASDAQ:NVAX)

Monaco Asset Management SAM decreased its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 55.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,000 shares of the biopharmaceutical company’s stock after selling 103,900 shares during the period. Monaco Asset Management SAM owned about 0.06% of Novavax worth $1,076,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of NVAX. Susquehanna Fundamental Investments LLC bought a new stake in Novavax during the 1st quarter worth approximately $1,499,000. Edgestream Partners L.P. increased its stake in shares of Novavax by 23.7% in the first quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 2,447 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Novavax by 29.9% in the first quarter. ProShare Advisors LLC now owns 37,203 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 8,570 shares during the last quarter. Swiss National Bank lifted its position in Novavax by 17.1% during the 1st quarter. Swiss National Bank now owns 211,000 shares of the biopharmaceutical company’s stock worth $1,009,000 after buying an additional 30,800 shares in the last quarter. Finally, Allianz Asset Management GmbH lifted its position in Novavax by 45.9% during the 4th quarter. Allianz Asset Management GmbH now owns 634,692 shares of the biopharmaceutical company’s stock worth $3,047,000 after buying an additional 199,771 shares in the last quarter. Institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

NVAX has been the subject of several research reports. JPMorgan Chase & Co. raised their price objective on shares of Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Monday, May 13th. TD Cowen upped their price objective on Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a report on Monday, May 13th. B. Riley reissued a “buy” rating and issued a $23.00 target price (down from $25.00) on shares of Novavax in a research note on Monday, August 12th. Finally, Bank of America upped their price target on Novavax from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Friday, June 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $15.80.

Insider Activity

In related news, Director James F. Young sold 7,500 shares of Novavax stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $14.09, for a total transaction of $105,675.00. Following the transaction, the director now owns 61,760 shares of the company’s stock, valued at approximately $870,198.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by company insiders.

Novavax Stock Performance

Shares of Novavax stock opened at $12.78 on Tuesday. The firm has a fifty day moving average of $12.96 and a two-hundred day moving average of $10.26. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -4.03 and a beta of 2.04. Novavax, Inc. has a 52 week low of $3.53 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million during the quarter, compared to analyst estimates of $458.57 million. During the same period in the previous year, the company earned $0.58 EPS. The company’s revenue was down 2.1% compared to the same quarter last year. As a group, research analysts forecast that Novavax, Inc. will post -1.04 EPS for the current fiscal year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.